Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
14.20
-0.29 (-2.00%)
Dec 5, 2025, 4:00 PM EST - Market closed
Amylyx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Amylyx Pharmaceuticals stock have an average target of 17.43, with a low estimate of 8.00 and a high estimate of 25. The average target predicts an increase of 22.75% from the current stock price of 14.20.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amylyx Pharmaceuticals stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $16 → $20 | Strong Buy | Maintains | $16 → $20 | +40.85% | Nov 7, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $12 → $20 | Strong Buy | Maintains | $12 → $20 | +40.85% | Oct 17, 2025 |
| Baird | Baird | Buy Maintains $10 → $19 | Buy | Maintains | $10 → $19 | +33.80% | Oct 16, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $14 → $16 | Strong Buy | Maintains | $14 → $16 | +12.68% | Oct 3, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $10 → $20 | Strong Buy | Maintains | $10 → $20 | +40.85% | Sep 16, 2025 |
Financial Forecast
Revenue This Year
n/a
from 87.37M
Revenue Next Year
n/a
EPS This Year
-1.61
from -4.43
EPS Next Year
-1.40
from -1.61
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.51 | -1.05 | ||||
| Avg | -1.61 | -1.40 | ||||
| Low | -1.71 | -1.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.